MedTrace Logo

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

NCT06703177 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 876

Last updated 2025-12-03

No results posted yet for this study

Summary

This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.

Conditions

Interventions

DRUG

SHR-1826

SHR-1826

DRUG

SHR-4642

SHR-4642

DRUG

SHR-9839

SHR-9839

DRUG

SHR-8068

SHR-8068

DRUG

Bevacizumab Injection

Bevacizumab Injection

DRUG

Fluorouracil Injection

Fluorouracil Injection

DRUG

Calcium Folinate Injection

Calcium Folinate Injection

DRUG

Adebrelimab Injection

Adebrelimab Injection

DRUG

Capecitabine tablets

Capecitabine tablets, oral.

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-18
Primary Completion
2026-01-01
Completion
2027-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06703177 on ClinicalTrials.gov